Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-03-07

Clinical Trial Update: Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men [Phase 3]

View source ↗

Summary

Phase 3 long-term safety study of intramuscular testosterone undecanoate in hypogonadal men has completed; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • testosterone undecanoate (testosterone undecanoate)

Snippet

Sponsor: Endo Pharmaceuticals | Conditions: Hypogonadism, Primary Hypogonadism | Phase 3 | Status: COMPLETED | Results posted: 2017-03-07